Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG192

—

2a7dd2d6-d9d6-51a1-b2dc-a0b0bc32955e

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.565
  • E2F_TARGETS+0.349
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340
  • G2M_CHECKPOINT+0.295
  • MYC_TARGETS_V1+0.251
  • PANCREAS_BETA_CELLS+0.218
  • SPERMATOGENESIS+0.210
  • GLYCOLYSIS+0.206
  • KRAS_SIGNALING_DN+0.199
  • MTORC1_SIGNALING+0.193

Top 10 suppressed

  • TGF_BETA_SIGNALING-0.409
  • UV_RESPONSE_DN-0.361
  • PROTEIN_SECRETION-0.334
  • ANDROGEN_RESPONSE-0.294
  • INTERFERON_ALPHA_RESPONSE-0.236
  • HEME_METABOLISM-0.201
  • NOTCH_SIGNALING-0.174
  • APOPTOSIS-0.149
  • FATTY_ACID_METABOLISM-0.142
  • APICAL_JUNCTION-0.125

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-22-1012-01A-01R-0692-07
lung-landscapes@6
—cohortSQ20.813
2SRR12202407
bladder-landscape@3
——0.801
3MNG158
mng-umap@100
——0.797
4MNG156
mng-umap@100
——0.781
5TCGA-A2-A3XX-01A-21R-A239-07
breast-umap@18
—E0.778
6MDT-AP-2494
medullo-epn-umap@date-based
MedMedulloblastoma0.754
7SRR1516100
bladder-landscape@3
——0.745
8MNG1082
mng-umap@100
——0.744
9MDT-AP-2281
medullo-epn-umap@date-based
MedMedulloblastoma0.742
10TCGA-BH-A0E6-01A-11R-A034-07
breast-umap@18
—E0.734

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 27 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.565Idelalisib— uncovered
E2F_TARGETS0.349Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.340Inavolisib— uncovered
G2M_CHECKPOINT0.295Inavolisib— uncovered
MYC_TARGETS_V10.251Inavolisib— uncovered
PANCREAS_BETA_CELLS0.218Cobimetinib— uncovered
SPERMATOGENESIS0.210Inavolisib— uncovered
GLYCOLYSIS0.206Inavolisib— uncovered
KRAS_SIGNALING_DN0.199Remibrutinib— uncovered
MTORC1_SIGNALING0.193Inavolisib— uncovered
UV_RESPONSE_UP0.193Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.160Remibrutinib— uncovered
INFLAMMATORY_RESPONSE0.154Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.145Inavolisib— uncovered
ALLOGRAFT_REJECTION0.129Idelalisib— uncovered
HYPOXIA0.123Idelalisib— uncovered
DNA_REPAIR0.118Idelalisib— uncovered
MYOGENESIS0.102Inavolisib— uncovered
COMPLEMENT0.083Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.081Idelalisib— uncovered